Suppr超能文献

溶酶体膜蛋白LGP85在内体和溶酶体形态的生物发生及维持中的作用。

A role for the lysosomal membrane protein LGP85 in the biogenesis and maintenance of endosomal and lysosomal morphology.

作者信息

Kuronita Toshio, Eskelinen Eeva-Liisa, Fujita Hideaki, Saftig Paul, Himeno Masaru, Tanaka Yoshitaka

机构信息

Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Maidashi 3-1-1, Fukuoka 812-8582, Japan.

出版信息

J Cell Sci. 2002 Nov 1;115(Pt 21):4117-31. doi: 10.1242/jcs.00075.

Abstract

LGP85 (LIMP II) is a type III transmembrane glycoprotein that is located primarily in the limiting membranes of lysosomes and late endosomes. Despite being the abundant molecule of these compartments, whether LGP85 merely resides as one of the constituents of these membranes or plays a role in the regulation of endosome and lysosome biogenesis remains unclear. To elucidate these questions, we examined the effects of overexpression of LGP85 on the morphology and membrane traffic of the endosomal/lysosomal system. Here we demonstrate that overexpression of LGP85 causes an enlargement of early endosomes and late endosomes/lysosomes. Such a morphological alteration was not observed by overexpression of other lysosomal membrane proteins, LGP107 (LAMP-1) or LGP96 (LAMP-2), reflecting a LGP85-specific function. We further demonstrate that overexpression of LGP85 impairs the endocytic membrane traffic out of these enlarged compartments, which may be correlated with or account for the accumulation of cholesterol observed in these compartments. Interestingly, co-transfection of LGP85 and the dominant-negative form of Rab5b (Rab5bS34N) abolished the formation of large vacuoles, suggesting that the GTP-bound active form of Rab5b is involved in the enlargement of endosomal/lysosomal compartments induced by overexpression of LGP85. Thus, these findings provide important new insights into the role of LGP85 in the biogenesis and the maintenance of endosomes/lysosomes. We conclude that LGP85 may participate in reorganizing the endosomal/lysosomal compartments.

摘要

LGP85(LIMP II)是一种III型跨膜糖蛋白,主要位于溶酶体和晚期内体的界膜中。尽管它是这些区室中的丰富分子,但LGP85仅仅作为这些膜的组成成分之一存在,还是在内体和溶酶体生物发生的调节中发挥作用,仍不清楚。为了阐明这些问题,我们研究了LGP85过表达对内体/溶酶体系统形态和膜运输的影响。在此我们证明,LGP85过表达导致早期内体和晚期内体/溶酶体增大。过表达其他溶酶体膜蛋白LGP107(LAMP-1)或LGP96(LAMP-2)未观察到这种形态改变,这反映了LGP85的特异性功能。我们进一步证明,LGP85过表达损害了从这些增大的区室向外的内吞膜运输,这可能与在这些区室中观察到的胆固醇积累相关或导致了这种积累。有趣的是,LGP85与Rab5b的显性负性形式(Rab5bS34N)共转染消除了大液泡的形成,表明Rab5b的GTP结合活性形式参与了由LGP85过表达诱导的内体/溶酶体区室增大。因此,这些发现为LGP85在内体/溶酶体生物发生和维持中的作用提供了重要的新见解。我们得出结论,LGP85可能参与内体/溶酶体区室的重组。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验